TG Therapeutics Inc. Common Stock (TGTX)

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsin…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

399

Website

www.tgtherapeutics.com/

Fundamentals

1-day range

$50.71$52.34

Market cap

$7.59B

P/E (trailing)

16.62

P/E (forward)

17.43

EPS (trailing)

$2.75

Dividend yield

—

Beta

1.80

Avg. volume

2.37M

Forecasts

7 analyst ratings

TG Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TGTX

  TG Therapeutics Inc. Common Stock

  $53.91

  ▼ 3.25%
  Market cap $7.59BP/E 16.62
  $26.76$59.3
• RYTM

  Rhythm Pharmaceuticals Inc. Common Stock

  $107.23

  ▼ 4.71%
  Market cap $7.72BP/E —
  $74.5$122.2
• COGT

  Cogent Biosciences Inc. Common Stock

  $34.68

  ▼ 6.50%
  Market cap $7.14BP/E —
  $11.6$43.73
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.32BP/E —
  $62.18$200
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.25BP/E —
  $1.33$24.28
• DNTH

  Dianthus Therapeutics Inc. Common Stock

  $105.72

  ▼ 5.22%
  Market cap $6.15BP/E —
  $22.81$117.88
• SYRE

  Spyre Therapeutics Inc. Common Stock

  $90.4

  ▼ 3.43%
  Market cap $9.12BP/E —
  $14.51$110.18

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
  SeekingAlpha · 8/22/2026
• Watching TG Therapeutics; Traders Speculate Multiple Parties Interested To Acquire TG Therapeutics
  benzinga · 8/21/2026
• MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday
  Benzinga · 8/21/2026
• TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth with a Breakout Setup
  ChartMill · 8/19/2026
• JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72
  Benzinga · 8/7/2026
• TG Therapeutics: Why I'm Staying Long After The Q2 Selloff
  SeekingAlpha · 8/3/2026
• TG Therapeutics (NASDAQ:TGTX) Falls as Q2 Revenue Beats but EPS Misses, Guidance Raised Below Estimates
  ChartMill · 8/3/2026
• TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/3/2026
• TG Therapeutics Raises FY2026 Sales Guidance from $925.000M to $950.000M vs $942.370M Est
  Benzinga · 8/3/2026

• Lonial Sagar · June 11, 2026 · Grant

  8.3K
• HUME DANIEL · June 11, 2026 · Grant

  8.3K
• Hoberman Kenneth · June 11, 2026 · Grant

  8.3K
• Echelard Yann · June 11, 2026 · Grant

  8.3K
• Charney Laurence N · June 11, 2026 · Grant

  8.3K

Institutional Ownership

March 31, 2026

Total shares held

99.97M

Total value held

$3.26B

Institutional holders

355